Disease modifying drugs for rheumatological diseases: a brief history of everything

被引:6
作者
Giles, Joanna L. [1 ]
Polak, Oktawia J. [1 ]
Landon, John [1 ]
机构
[1] MicroPharm Ltd, Newcastle Emlyn, Carmarthenshire, Australia
来源
INFLAMMATORY DISORDERS - PT B | 2020年 / 120卷
关键词
TUMOR-NECROSIS-FACTOR; JUVENILE IDIOPATHIC ARTHRITIS; INTERLEUKIN-12/23; MONOCLONAL-ANTIBODY; ACTIVE PSORIATIC-ARTHRITIS; B-CELL DEPLETION; FREE H CHAINS; RHEUMATOID-ARTHRITIS; DOUBLE-BLIND; SYNOVIAL-FLUID; FACTOR-ALPHA;
D O I
10.1016/bs.apcsb.2019.11.007
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The rheumatological diseases are a group of chronic, painful, degenerative and debilitating conditions with an increasing prevalence across the globe. The pathogenesis of these disorders is complex, overlapping and not fully understood. As such, it is difficult and time consuming to achieve correct diagnosis and complete remission for an individual patient. In this review we describe the most common forms of inflammatory arthritis and discuss how the management and treatment options for these rheumatic diseases have developed over time. We outline the successes and the limitations of current treatment regimens and discuss the economic burden of the current options. With advancements in understanding of disease mechanisms, we discuss the importance of the biologics revolution in the context of rheumatological disease and how the development of biosimilars and small molecule inhibitors will impact current treatment options in order to alleviate some of the cost burden of biological therapies. The ideal treatment strategy for the future would involve personalized and predictive medicine where by treatments can be tailored to an individual patient's needs in order to achieve fast and successful remission with no adverse events.
引用
收藏
页码:313 / 348
页数:36
相关论文
共 131 条
  • [1] Influence of Matrix metalloproteinase 1 and 3 genetic variations on susceptibility and severity of juvenile idiopathic arthritis
    Abd-Allah, Somia H.
    El-Shal, Amal S.
    Shalaby, Sally M.
    Pasha, Heba F.
    Abou El-Saoud, Amany M.
    Galil, Sahar M. Abdel
    Mahmoud, Tysser A.
    [J]. IUBMB LIFE, 2015, 67 (12) : 934 - 942
  • [2] CTLA-4-Ig Therapy Diminishes the Frequency but Enhances the Function of Treg Cells in Patients with Rheumatoid Arthritis
    Alvarez-Quiroga, Crisol
    Abud-Mendoza, Carlos
    Doniz-Padilla, Lesly
    Juarez-Reyes, Amida
    Monsivais-Urenda, Adriana
    Baranda, Lourdes
    Gonzalez-Amaro, Roberto
    [J]. JOURNAL OF CLINICAL IMMUNOLOGY, 2011, 31 (04) : 588 - 595
  • [3] Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease
    Ansari, A
    Hassan, C
    Duley, J
    Marinaki, A
    Shobowale-Bakre, EM
    Seed, P
    Meenan, J
    Yim, A
    Sanderson, J
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2002, 16 (10) : 1743 - 1750
  • [4] PREVALENCE, ONSET, AND RISK OF PSYCHIATRIC-DISORDERS IN MEN WITH CHRONIC LOW-BACK-PAIN - A CONTROLLED-STUDY
    ATKINSON, JH
    SLATER, MA
    PATTERSON, TL
    GRANT, I
    GARFIN, SR
    [J]. PAIN, 1991, 45 (02) : 111 - 121
  • [5] Barton A, 2001, ARTHRITIS RHEUM, V44, P61, DOI 10.1002/1529-0131(200101)44:1<61::AID-ANR9>3.0.CO
  • [6] 2-Q
  • [7] A history of immune globulin therapy, from the harvard crash program to monoclonal antibodies
    Berger M.
    [J]. Current Allergy and Asthma Reports, 2002, 2 (5) : 368 - 378
  • [8] PASSIVE-IMMUNIZATION AGAINST CACHECTIN TUMOR NECROSIS FACTOR PROTECTS MICE FROM LETHAL EFFECT OF ENDOTOXIN
    BEUTLER, B
    MILSARK, IW
    CERAMI, AC
    [J]. SCIENCE, 1985, 229 (4716) : 869 - 871
  • [9] BLEYER WA, 1978, CANCER-AM CANCER SOC, V41, P36, DOI 10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO
  • [10] 2-I